- Conditions
- Hemophilia A
- Interventions
- rFVIIIFc
- Biological
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- Up to 5 Years · Male only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Duarte, California • Sacramento, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hemophilia A
- Interventions
- Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980), Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 12 Years to 60 Years · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 2
- States / cities
- Davis, California • Orange, California
- Conditions
- Hemophilia A
- Interventions
- Antihemophilic factor, recombinant, manufactured protein-free
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Peoria, Illinois + 5 more
- Conditions
- Hemophilia A
- Interventions
- rFVIII (BAY81-8973) on demand, rFVIII (BAY81-8973) prophylaxis low-dose, rFVIII (BAY81-8973) prophylaxis high-dose
- Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 12 Years to 65 Years · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Dayton, Ohio • Houston, Texas
- Conditions
- Hemophilia A
- Interventions
- Nuwiq (low dose protocol), HEMLIBRA, Nuwiq (Atlanta protocol)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Severe Hemophilia A
- Interventions
- rFVIIIFc
- Drug
- Lead sponsor
- Bioverativ Therapeutics Inc.
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Sacramento, California • Waltham, Massachusetts + 2 more
- Conditions
- Hemophilia, Menstrual Flow Excessive
- Interventions
- Recombinant FVIII Fc fusion product Eloctate, Recombinant FIX Fc fusion product Alprolix, Patient-operated diagnostic device for anemia AnemoCheck.
- Drug · Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 14 Years to 55 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Hemophilia A
- Interventions
- PEGylated Recombinant Factor VIII, ITI
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- Up to 5 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Cupertino, California • Oakland, California + 17 more
- Conditions
- Hemophilia A
- Interventions
- Advate (Low Dose), Advate (High Dose), BIVV001 (Low Dose), BIVV001 (High Dose)
- Biological
- Lead sponsor
- Bioverativ, a Sanofi company
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 4 more
- Conditions
- Hemophilia A With Inhibitors
- Interventions
- Factor VIII concentrates, Low-dose treatment, High-dose treatment
- Drug · Other
- Lead sponsor
- New York Presbyterian Hospital
- Other
- Eligibility
- Up to 7 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Duarte, California • Orange, California + 31 more
- Conditions
- Hemophilia A, Prophylaxis of Bleeding
- Interventions
- Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).
- Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Loma Linda, California • Los Angeles, California • Aurora, Colorado + 8 more
- Conditions
- Hemophilia A
- Interventions
- Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- Up to 1 Year · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • New Brunswick, New Jersey